We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
Email registered. Please sign in.×
Enter your contact to build trust with supplier(s)×
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Chongqing Quanxinxiangsheng Bio-pharmaceutical CO., LTD , established in 1995, is a manufacture of bio-pharmaceuticals (enzymes).
The company has enjoyed good reputation in Chinese market for about 2 decades .Now it is the biggest supplier of Pepsin and pancreatin in China.
The company covers an area of nearly 40 Mu, buildings nearly 8000 squaremeters, the green area of the factory is more than 40%, a beautiful environment.
The company is mainly specialized in developing and manufacturing APIenzymes) extracted from animal organs , has been authorized with the GMP certificate issued by the State Food and Drug Administration and built a strict qualitycontrol system covering purchase of raw materials, production processing, sales andafter-sales service .
There are about 70 employees in the company.Well-educations workers take a share of 17%, the staffs of primary andintermediate title occupy 15.5% , everyone has been well-trained.
We are committed to health of human bening.Nowadays we are looking for the distributors,agencies and end users worldwide who areinterested in our products. Be sure that wewould be the trustful suppliers of animal enzymes with competitive cost control.
Eight years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
